睡眠障碍症状对抑郁症混合认知行为疗法治疗结果的影响(e - compa卡塔尔世界杯8强波胆分析re研究):二级分析%A Jensen,Esben Skov %A Ladegaard,Nicolai %A Mellentin,Angelina Isabella %A Ebert,David Daniel %A Titzler,Ingrid %A Araya,Ricardo %A Cerga Pashoja,Arlinda %A Hazo,Jean-Baptiste %A Holtzmann,Jérôme %A Cieslak,Roman %A Smoktunowicz,Ewelina %A Baños,Rosa %A Herrero,Rocio %A García-Palacios,Azucena %A bottella,Cristina %A Berger,Thomas %A Krieger,Tobias %A Holmberg,Trine Theresa %A Topooco,Naira %A Andersson,Gerhard %A van Straten,Annemieke %A Kemmeren,Lise %A Kleiboer,Annet %ARiper,Heleen %A Mathiasen,Kim %+丹麦欧登塞南丹麦精神卫生服务远程精神病学中心，1 61677747,kmathiasen@health.sdu.dk %K混合护理%K bCBT %K认知行为治疗%K数字干预%K重度抑郁症%K睡眠障碍%K睡眠障碍%K心理健康%K数字健康%K手机%D 2022 %7 21.3.2022 %9原文%J J Med Internet Res %G英语%X睡眠障碍症状在重度抑郁症(MDD)中很常见，并且已经发现它阻碍了传统的面对面心理治疗(如认知行为疗法)的治疗效果。为了增加循证治疗的传播，由网络和面对面治疗组成的混合认知行为疗法(bbct)在重度抑郁症患者中的应用正在增加。迄今为止，还没有研究检查睡眠障碍症状是否对bCBT治疗结果有影响，以及它是否对bCBT和常规治疗(TAU)有同样的影响。目的:本研究的目的是探讨基线睡眠障碍症状是否独立于治疗方式对治疗结果的影响，以及睡眠障碍症状对常规护理中bbct和TAU的影响是否相同。方法:该研究基于e - compare(欧洲抑郁症混合治疗与常规治疗比较疗效研究)研究的数据，这是一项2组、多地点、平行、随机对照、非劣效性试验。共有943例MDD门诊患者被随机分为bbct组(476/943,50.5%)和TAU组(467/943,49.5%)。本研究的主要结果是在12个月的随访中抑郁症状严重程度的变化。 The secondary outcomes were the change in depression symptom severity at the 3- and 6-month follow-up and MDD diagnoses at the 12-month follow-up, assessed using the Patient Health Questionnaire-9 and Mini-International Neuropsychiatric Interview, respectively. Mixed effects models were used to examine the association of sleep disturbance symptoms with treatment outcome and treatment modality over time. Results: Of the 943 patients recruited for the study, 558 (59.2%) completed the 12-month follow-up assessment. In the total sample, baseline sleep disturbance symptoms did not significantly affect change in depressive symptom severity at the 12-month follow-up (β=.16, 95% CI –0.04 to 0.36). However, baseline sleep disturbance symptoms were negatively associated with treatment outcome for bCBT (β=.49, 95% CI 0.22-0.76) but not for TAU (β=–.23, 95% CI −0.50 to 0.05) at the 12-month follow-up, even when adjusting for baseline depression symptom severity. The same result was seen for the effect of sleep disturbance symptoms on the presence of depression measured with Mini-International Neuropsychiatric Interview at the 12-month follow-up. However, for both treatment formats, baseline sleep disturbance symptoms were not associated with depression symptom severity at either the 3- (β=.06, 95% CI −0.11 to 0.23) or 6-month (β=.09, 95% CI −0.10 to 0.28) follow-up. Conclusions: Baseline sleep disturbance symptoms may have a negative impact on long-term treatment outcomes in bCBT for MDD. This effect was not observed for TAU. These findings suggest that special attention to sleep disturbance symptoms might be warranted when MDD is treated with bCBT. Future studies should investigate the effect of implementing modules specifically targeting sleep disturbance symptoms in bCBT for MDD to improve long-term prognosis. %M 35311687 %R 10.2196/30231 %U //www.mybigtv.com/2022/3/e30231 %U https://doi.org/10.2196/30231 %U http://www.ncbi.nlm.nih.gov/pubmed/35311687